Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) Beneish M-Score: -2.59 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301126 Hunan Dajiaweikang Pharmaceutical Industry Co Ltd SZSE:301126
68 GF Score
Price ¥9.00
GF Value ¥12.31
Valuation Modestly Undervalued
! 11 Warning Signs
View Full Analysis

What is Hunan Dajiaweikang Pharmaceutical Industry Co Beneish M-Score?

Hunan Dajiaweikang Pharmaceutical Industry Co SZSE:301126 +3.57% 68 Beneish M-Score is -2.59 as of Aug. 01, 2026. GuruFocus rates SZSE:301126 with a GF Score™ of 68/100 and a GF Value™ of ¥12.31 (Modestly Undervalued). The stock has 11 warning signs investors should review. Among 625 Healthcare Providers & Services companies, Hunan Dajiaweikang Pharmaceutical Industry Co ranks better than 50.72% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.59 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Hunan Dajiaweikang Pharmaceutical Industry Co's Beneish M-Score or its related term are showing as below:

SZSE:301126' s Beneish M-Score Range Over the Past 10 Years
Min: -12.97   Med: -2.4   Max: -0.18
Current: -2.59

During the past 13 years, the highest Beneish M-Score of Hunan Dajiaweikang Pharmaceutical Industry Co was -0.18. The lowest was -12.97. And the median was -2.40.


Hunan Dajiaweikang Pharmaceutical Industry Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Hunan Dajiaweikang Pharmaceutical Industry Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hunan Dajiaweikang Pharmaceutical Industry Co Beneish M-Score Chart

Hunan Dajiaweikang Pharmaceutical Industry Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.74 -0.46 -2.05 -2.64 -2.40

Hunan Dajiaweikang Pharmaceutical Industry Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.56 -2.60 -2.46 -2.40 -2.59

Hunan Dajiaweikang Pharmaceutical Industry Co Beneish M-Score Competitor Comparison

For the Pharmaceutical Retailers subindustry, Hunan Dajiaweikang Pharmaceutical Industry Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Dajiaweikang Pharmaceutical Industry Co Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Hunan Dajiaweikang Pharmaceutical Industry Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Hunan Dajiaweikang Pharmaceutical Industry Co's Beneish M-Score falls into.


SZSE:301126
68GF Score
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd SZSE:301126
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hunan Dajiaweikang Pharmaceutical Industry Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Hunan Dajiaweikang Pharmaceutical Industry Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0753+0.528 * 1.0672+0.404 * 0.9079+0.892 * 0.9954+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9479+4.679 * -0.035029-0.327 * 1.0485
=-2.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥2,396 Mil.
Revenue was 1384.201 + 1014.152 + 1421.748 + 1408.517 = ¥5,229 Mil.
Gross Profit was 238.431 + 232.883 + 255.351 + 223.392 = ¥950 Mil.
Total Current Assets was ¥4,078 Mil.
Total Assets was ¥6,393 Mil.
Property, Plant and Equipment(Net PPE) was ¥953 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥253 Mil.
Total Current Liabilities was ¥4,032 Mil.
Long-Term Debt & Capital Lease Obligation was ¥731 Mil.
Net Income was 5.965 + -247.556 + 4.204 + -2.251 = ¥-240 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -67.974 + 39.096 + -32.778 + 45.95 = ¥-16 Mil.
Total Receivables was ¥2,239 Mil.
Revenue was 1299.821 + 1250.164 + 1383.095 + 1319.693 = ¥5,253 Mil.
Gross Profit was 224.714 + 276.366 + 264.757 + 252.714 = ¥1,019 Mil.
Total Current Assets was ¥3,979 Mil.
Total Assets was ¥6,443 Mil.
Property, Plant and Equipment(Net PPE) was ¥951 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥268 Mil.
Total Current Liabilities was ¥3,199 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,379 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2396.197 / 5228.618) / (2238.734 / 5252.773)
=0.458285 / 0.4262
=1.0753

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1018.551 / 5252.773) / (950.057 / 5228.618)
=0.193907 / 0.181703
=1.0672

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4077.548 + 952.898) / 6392.702) / (1 - (3979.298 + 951.448) / 6443.039)
=0.213095 / 0.234717
=0.9079

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5228.618 / 5252.773
=0.9954

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 951.448)) / (0 / (0 + 952.898))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(252.585 / 5228.618) / (267.691 / 5252.773)
=0.048308 / 0.050962
=0.9479

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((730.521 + 4032.304) / 6392.702) / ((1378.754 + 3199.424) / 6443.039)
=0.745041 / 0.710562
=1.0485

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-239.638 - 0 - -15.706) / 6392.702
=-0.035029

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Hunan Dajiaweikang Pharmaceutical Industry Co has a M-score of -2.59 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.59 mean?
Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) has a Beneish M-Score of -2.59 as of Aug. 01, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Hunan Dajiaweikang Pharmaceutical Industry Co and its competitors. According to the industry distribution chart, Hunan Dajiaweikang Pharmaceutical Industry Co ranks #308 out of 625 companies in the Healthcare Providers & Services industry, placing it in the top 49.3%.
Is Hunan Dajiaweikang Pharmaceutical Industry Co's Beneish M-Score too high?
Hunan Dajiaweikang Pharmaceutical Industry Co's current Beneish M-Score is -2.59. Based on the distribution chart, Hunan Dajiaweikang Pharmaceutical Industry Co ranks #308 out of 625 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Hunan Dajiaweikang Pharmaceutical Industry Co has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Dajiaweikang Pharmaceutical Industry Co's Beneish M-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Hunan Dajiaweikang Pharmaceutical Industry Co ranks #308 out of 625 companies for Beneish M-Score. This puts Hunan Dajiaweikang Pharmaceutical Industry Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Hunan Dajiaweikang Pharmaceutical Industry Co and its competitors. Hunan Dajiaweikang Pharmaceutical Industry Co's current Beneish M-Score is -2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Dajiaweikang Pharmaceutical Industry Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥12.31, compared to a current price of ¥9.00 — trading 26.9% below its estimated fair value. The current Beneish M-Score is -2.59. Hunan Dajiaweikang Pharmaceutical Industry Co's overall GF Score™ is 68/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126), the current Beneish M-Score is -2.59 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hunan Dajiaweikang Pharmaceutical Industry Co (SZSE:301126) Overvalued in 2026?

Based on GuruFocus' analysis, Hunan Dajiaweikang Pharmaceutical Industry Co stock appears to be undervalued. The current stock price of ¥9.00 is trading 26.9% below its estimated GF Value™ of ¥12.31. GuruFocus considers Hunan Dajiaweikang Pharmaceutical Industry Co to be Modestly Undervalued.

Key valuation signals for SZSE:301126:

  • Beneish M-Score: -2.59
  • GF Value™: ¥12.31 vs. price of ¥9.00 (26.9% below fair value)
  • GF Score™: 68/100 with 11 warning signs

No single metric tells the full story. See the SZSE:301126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hunan Dajiaweikang Pharmaceutical Industry Co Business Description

Address No. 30 Fuling Road, Yuelu District, Hunan Province, Changsha, CHN, 410000
Hunan Dajiaweikang Pharmaceutical Industry Co Ltd is engaged in the distribution and retail of pharmaceuticals, biological products, medical equipment and other products.
68GF Score

Get the complete analysis for SZSE:301126

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.00
Price
¥12.31
GF Value